| Inhibition of human recombinant ATP-citrate lyase - BioAssay Summary A novel series of 2-hydroxy-N-arylbenzenesulfonamides were identified to be ATP-citrate lyase (ACL) inhibitors with compound 9 displaying potent in vitro activity (IC(50)=0.13 microM). Chronic oral dosing of compound 9 in high-fat fed mice lowered plasma cholesterol, triglyceride, and glucose, as well as inhibited weight gain. ..more |
_ | Related BioAssays Related BioAssays |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Target
BioActive Compounds: 13 Description: Title: 2-hydroxy-N-arylbenzenesulfonamides as ATP-citrate lyase inhibitors. Abstract: A novel series of 2-hydroxy-N-arylbenzenesulfonamides were identified to be ATP-citrate lyase (ACL) inhibitors with compound 9 displaying potent in vitro activity (IC(50)=0.13 microM). Chronic oral dosing of compound 9 in high-fat fed mice lowered plasma cholesterol, triglyceride, and glucose, as well as inhibited weight gain. (PMID: 17383874) Comment Compounds with activity <= 50uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation. Categorized Comment ChEMBL Assay Type: Binding ChEMBL Assay Data Source: Scientific Literature ChEMBL Target ID: 12028 ChEMBL target type: Target is a single protein chain Result Definitions
* Activity Concentration. Data Table (Concise) Classification
PageFrom: |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||